Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma
HNO · 2024
DOI: 10.1007/s00106-023-01404-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift HNO, 2024. Verfasst von Tristan Römer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, Center for Integrated Oncology Aachen Bonn Cologne Düsseld…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Induction Chemotherapy, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RWTH Aachen University.
Themen: Onkologische Pflege, Kinderkrankenpflege
Abstract (Originalsprache)
Background
Treatment of Epstein-Barr virus(EBV)-positive nasopharyngeal carcinoma (NPC) with cisplatin/5-fluorouracil (5-FU) induction chemotherapy, followed by radiochemotherapy and subsequent interferon‑β, has yielded high survival rates in children, adolescents, and young adults. A previous study has shown that reduction of radiation dose from 59.4 to 54.0 Gy appears to be safe in patients with complete response (CR) to induction chemotherapy. As immune checkpoint-inhibitors have shown activity in NPC, we hypothesize that the addition of nivolumab to standard induction chemotherapy would increase the rate of complete tumor responses, thus allowing for a reduced radiation dose in a greater proportion of patients.
Methods
This is a prospective multicenter phase 2 clinical trial including pediatric and adult patients with their first diagnosis of EBV-positive NPC, scheduled to receive nivolumab in addition to standard induction chemotherapy. In cases of non-response to induction therapy (stable or progressive disease), and in patients with initial distant metastasis, treatment with nivolumab will be continued during radiochemotherapy. Primary endpoint is tumor response on magnetic resonance imaging (MRI) and positron emission tomography (PET) after three cycles of induction chemotherapy. Secondary endpoints are event-free (EFS) and overall survival (OS), safety, and correlation of tumor response with programmed cell death ligand 1 (PD-L1) expression.
Discussion
As cure rates in localized EBV-positive NPC today are high with standard multimodal treatment, the focus increasingly shifts toward prevention of late effects, the burden of which is exceptionally high, mainly due to intense radiotherapy. Furthermore, survival in patients with metastatic disease and resistant to conventional chemotherapy remains poor. Primary objective of this study is to investigate whether the addition of nivolumab to standard induction chemotherapy in children and adults with EBV-positive NPC is able to increase the rate of complete responses, thus enabling a reduction in radiation dose in more patients, but also offer patients with high risk of treatment failure the chance to benefit from the addition of nivolumab.
Trial registration
EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) No. 2021-006477-32.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), RWTH Aachen University, Aachen, Germany.
- Section of Pediatric Pathology, Department of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University Hospital Bonn, Bonn, Germany.
- Section of Pediatric Radiology, University Medical Center Mainz, Mainz, Germany.
- Department of Nuclear Medicine, Medical Faculty, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), RWTH Aachen University, Aachen, Germany.
- Department of Radiotherapy and Radiation Oncology, Hannover Medical School, Hannover, Germany.
- Department of Radiation Oncology, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), RWTH Aachen University, Aachen, Germany.
Förderung
- RWTH Aachen University
Zitieren
APA
Römer, T., Vokuhl, C., Staatz, G., Mottaghy, F. M., Christiansen, H., Eble, M. J., Timmermann, B., Klussmann, J. P., Elbracht, M., Calaminus, G., Zimmermann, M., Brümmendorf, T. H., Feuchtinger, T., Kerp, H., & Kontny, U. (2024). Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma. HNO. https://doi.org/10.1007/s00106-023-01404-9
Vancouver
Römer T, Vokuhl C, Staatz G, Mottaghy FM, Christiansen H, Eble MJ, et al. Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma. HNO. 2024. doi:10.1007/s00106-023-01404-9
BibTeX
@article{Rmer2024,
author = {Römer, Tristan and Vokuhl, Christian and Staatz, Gundula and Mottaghy, Felix M and Christiansen, Hans and Eble, Michael J and Timmermann, Beate and Klussmann, Jens Peter and Elbracht, Miriam and Calaminus, Gabriele and Zimmermann, Martin and Brümmendorf, Tim H and Feuchtinger, Tobias and Kerp, Helena and Kontny, Udo},
title = {Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma},
journal = {HNO},
year = {2024},
doi = {10.1007/s00106-023-01404-9}
}
EUVIMED